NVRO
vs
S&P 500
NVRO
S&P 500
Over the past 12 months, NVRO has underperformed S&P 500, delivering a return of +2% compared to the S&P 500's +12% growth.
Stocks Performance
NVRO vs S&P 500
Performance Gap
NVRO vs S&P 500
Performance By Year
NVRO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Nevro Corp
Glance View
Nevro Corp. engages in the provision of medical devices. The company is headquartered in Redwood City, California and currently employs 945 full-time employees. The company went IPO on 2014-11-06. The firm has developed and commercialized the Senza spinal cord stimulation (SCS) system. SCS is a neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform, which is in addition to the Senza family of products. The Company’s solution for chronic pain includes 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain based on what it believes to be the best clinical evidence available. The advantages of its 10 kHz Therapy over traditional SCS include demonstrated superior efficacy data for both leg and back pain, paresthesia free pain relief for patients, anatomical lead placement for physicians, and ability to treat a broader group of chronic pain patients.
